Outlook Therapeutics, Inc.

OTLKSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1649989

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$1.4M	—	—	—	—
Cost of Goods and Services Sold	$1.4M	—	—	—	—
Gross Profit	$57.2K	—	—	—	—
Research and Development Expense	$41.8M	$26.5M	$42.3M	$39.0M	$26.3M
Selling, General and Administrative Expense	$29.9M	—	—	—	—
Operating Expenses	—	—	—	—	$36.8M
Operating Income (Loss)	-$71.7M	-$53.1M	-$63.1M	-$51.7M	-$36.8M
Interest Expense	—	—	—	—	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$28.8M	$32.3M	$28.5M	$22.8M	$19.7M
Assets, Current	$27.4M	$31.0M	$27.5M	$21.5M	$17.9M
Cash and Cash Equivalents, at Carrying Value	$14.9M	$23.4M	$17.4M	$14.5M	$12.5M
Accounts Receivable, after Allowance for Credit Loss, Current	$1.5M	—	—	—	—
Inventory, Net	$3.3M	—	—	—	—
Liabilities	$101.9M	$46.7M	$19.8M	$18.2M	$16.9M
Liabilities, Current	$42.6M	$46.7M	$19.7M	$6.8M	$15.9M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$68.8M	-$43.0M	-$56.7M	-$54.3M	-$31.8M
Net Cash Provided by (Used in) Investing Activities	—	—	—	—	-$900.0K
Net Cash Provided by (Used in) Financing Activities	$60.3M	$49.0M	$59.6M	$56.2M	$37.2M
Payments to Acquire Property, Plant, and Equipment	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)